ライフサイエンスコーパス: cidofovir

1 ting toxicity, particularly for adefovir and cidofovir.

2 mmunosuppression and treatment with low-dose cidofovir.

3 ted B-cell(-/-) mice with the antiviral drug cidofovir.

4 was resistant to ganciclovir, foscarnet, and cidofovir.

5 ganciclovir, valganciclovir, foscarnet, and cidofovir.

6 sporting the nucleotide analogs adefovir and cidofovir.

7 ted HHV-8 replication to a similar degree as cidofovir.

8 lues > or =30 microM and cross-resistance to cidofovir.

9 There was little net directional movement of cidofovir.

10 s ganciclovir followed by foscarnet and then cidofovir.

11 ted with in vitro cross-resistance of CMV to cidofovir.

12 for CMV isolates that are cross-resistant to cidofovir.

13 o ganciclovir, and 4 were cross-resistant to cidofovir.

14 events considered to be possibly related to cidofovir.

15 d for 50% inhibitory concentration (IC50) of cidofovir.

16 asing levels (from 5 to 75 micrograms/ml) of cidofovir.

17 ed that demonstrated increased resistance to cidofovir.

18 A543V had 10-fold reduced susceptibility to cidofovir.

19 ential antiviral drugs, as demonstrated with cidofovir.

20 ts included (val)ganciclovir, foscarnet, and cidofovir.

21 enhancement over the FDA-approved antiviral cidofovir.

22 ex virus (HSV) replication than acyclovir or cidofovir.

23 mmunosuppression reduction and half received cidofovir.

24 selectivity indexes that approximate that of cidofovir.

25 A synthesis apparatus that are distinct from cidofovir.

26 ted contribution to the urinary excretion of cidofovir.

27 seven patients were treated with intravenous cidofovir (0.20-0.50 mg/kg) every two to four weeks over

28 ients were treated with intravenous low-dose cidofovir (0.25-1 mg/kg per dose, every 2-3 weeks, witho

29 Cidofovir (0.3% or 1%) or placebo gel was applied once d

30 0.5% ketorolac tromethamine; group III, 0.5% cidofovir + 0.1% diclofenac sodium; and group IV, contro

31 cidofovir + artificial tears; group II, 0.5% cidofovir + 0.5% ketorolac tromethamine; group III, 0.5%

32 Cidofovir 1 mg/kg intravenously three times per week was

33 ceive treatment with electrocautery, topical cidofovir 1% ointment, or topical sinecatechins 10%.

34 ate hexahydrate) (IC50 = 80-100 microM), and cidofovir (1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]c

35 Cidofovir [1-[(S)-3-hydroxy-2-(phosphonomethoxy)propyl]c

36 ters of 99 000-2 500 000 copies/mL) received cidofovir; 1 died from complications relating to adenovi

37 6 eyes pretreated with liposome-encapsulated cidofovir 10-60 days before HSV-1 inoculation were prote

38 Cidofovir (100 micrograms) in liposomes (0.1 mL) was inj

39 Intravenous cidofovir, 5 mg/kg of body weight, once weekly for 2 wee

40 Moreover, treatment with cidofovir, a potent antiviral agent, robustly inhibits t

41 ed saturable, probenecid-sensitive uptake of cidofovir, adefovir, and other nucleoside phosphonate an

42 The single intravitreal injection of cidofovir administered was associated with transient neg

43 oted for HCMV during the various regimens of cidofovir administrated in this clinical trial.

44 red treatment group were eligible to receive cidofovir after progression of CMV retinitis was documen

45 in vitro studies indicating the efficacy of cidofovir against different adenovirus serotypes and sup

46 Treatment with cidofovir alone reduced viral load, but animals died fro

47 localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet.

48 eported in 31 (37%) of 84 patients allocated cidofovir and 39 (46%) of 84 patients assigned imiquimod

49 e study; 89 patients were randomly allocated cidofovir and 91 were assigned imiquimod.

50 The affinity of hOAT1 toward cidofovir and adefovir (K(m) = 46 and 30 microM, respect

51 nificantly contribute to the accumulation of cidofovir and adefovir in renal proximal tubules and, th

52 the dose-limiting clinical adverse effect of cidofovir and adefovir, two potent antiviral therapeutic

53 In the retina, cidofovir and an unknown metabolite were detected in the

54 1 (46%; 90% CI 37.0-55.3) patients allocated cidofovir and by 42 (46%; 37.2-55.3) patients assigned i

55 prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol c

56 Cidofovir and control were administered to both eyes twi

57 However, coadministration of cidofovir and Dryvax also reduced vaccine-elicited immun

58 ine efficacy showed that coadministration of cidofovir and Dryvax compromised the Dryvax-induced immu

59 Thus, the single-dose coadministration of cidofovir and Dryvax effectively controlled vaccination

60 Combined treatment with the antiviral drug cidofovir and etanercept, which targets tumor necrosis f

61 ldren, with BKVAN were treated with low-dose cidofovir and followed prospectively.

62 r resistance (<6-fold) but were sensitive to cidofovir and foscarnet, and 7 showed moderately reduced

63 o currently available antiherpesvirus drugs, cidofovir and foscarnet, had no effect on the transcript

64 S) conferred various levels of resistance to cidofovir and ganciclovir.

65 derately reduced susceptibility (<8-fold) to cidofovir and high-level resistance (8- to 23-fold) to g

66 Cidofovir and imiquimod were active, safe, and feasible

67 , and feasibility of two topical treatments--cidofovir and imiquimod--as an alternative to surgery in

68 the incremental health benefits and costs of cidofovir and immunosuppression reduction compared with

69 Cidofovir and Leflunomide are used empirically in the tr

70 The in vitro activity of Cidofovir and Leflunomide is modest, and the selectivity

71 mpared with those obtained with topical 0.5% cidofovir and saline.

72 ceptibilities to ganciclovir, foscarnet, and cidofovir and sequencing of UL97 and DNA polymerase were

73 ration at phosphorus in cyclic (S)-HPMPC (1, cidofovir) and (S)-HPMPA (2) phenyl ester (5 and 6, resp

74 ermore, antiviral treatment with CMX001 (HDP-cidofovir) and ST-246 protects when administered as a re

75 conferred resistance to both ganciclovir and cidofovir, and a mutation at codon 802 of Pol conferred

76 le resistance to ganciclovir, foscarnet, and cidofovir, and A543V had 10-fold reduced susceptibility

77 the organ-specific toxicity of adefovir and cidofovir, and indicates that CHOh OAT cells may represe

78 Despite treatment with corticosteroids, cidofovir, and intravenous immune globulin, PML progress

79 Cidofovir, and its prodrug brincidofovir, are inhibitors

80 Acyclovir, foscarnet, cidofovir, and PMEA reduced the number of cells expressi

81 Acyclic nucleotide phosphonates (adefovir, cidofovir, and tenofovir) are eliminated predominantly i

82 ptake likely plays a role in the etiology of cidofovir- and adefovir-associated nephrotoxicity, we at

83 pical treatment groups: 3% ddC; 2% ddC; 0.5% cidofovir; and saline.

84 Cidofovir appeared safe and effective for the treatment

85 ravitreal injection of liposome-encapsulated cidofovir appears to have a remarkably potent and prolon

86 ies including intravenous immunoglobulin and cidofovir are sparse.

87 ble antivirals ([val]ganciclovir, foscarnet, cidofovir) are associated with higher mortality in trans

88 led (36 in the electrocautery arm, 28 in the cidofovir arm, and 36 in the sinecatechins arm).

89 four masked treatment groups: group I, 0.5% cidofovir + artificial tears; group II, 0.5% cidofovir +

90 ation of topical corticosteroids and topical cidofovir as a desirable strategy for the treatment of s

91 ulating viral DNA replication and introduces cidofovir as a possible drug for controlling MCPyV infec

92 tially reported using ganciclovir and cyclic cidofovir as the prototype compounds.

93 n prior to, during, and after treatment with cidofovir, as well as species analysis of contemporaneou

94 travitreously injected with 20 micrograms of cidofovir at 5- to 6-week intervals.

95 Topical 1% and 0.5% cidofovir both appeared to be significantly more efficac

96 have evaluated therapeutic options including cidofovir, brincidofovir, and immunotherapy.

97 vity against mpox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat.

98 The lipid-conjugated prodrug of cidofovir, brincidofovir, has improved oral bioavailabil

99 A mutant exhibited an increased affinity for cidofovir but was not significantly different for PAH.

100 ptimal treatment strategies for BKVAN before cidofovir can be recommended strongly as routine therapy

101 vious studies showed that the CDV and cyclic cidofovir (cCDV) analogs 1-O-hexa-decyloxypropyl-CDV (HD

102 The acyclic nucleoside phosphonate cidofovir (CDV) and its closely related analogue (S)-9-(

103 We report our experience with cidofovir (CDV) for treatment of ADV infection in 57 HSC

104 Cidofovir (CDV) given by parenteral injection has been s

105 Group 1 was administered 1% cidofovir (CDV) twice a day for 3 days plus comfort tear

106 Cidofovir (CDV), a broad spectrum anti-DNA viral agent,

107 trial was conducted to test the activity of cidofovir (CDV), a drug with in vitro activity against K

108 We used cidofovir (CDV), a nucleotide-analogue KSHV DNA polymera

109 orally active ether lipid ester analogues of cidofovir (CDV)--hexadecyloxypropyl-CDV (HDP-CDV) and oc

110 determine the antiviral resistance of three cidofovir (CDV)-resistant variants of adenovirus type 5

111 Cidofovir [CDV; (S)-1-(3-hydroxy-2-phosphonomethoxyethyl

112 We also demonstrate that hexadecyloxypropyl-cidofovir (CMX001) rescues the hamsters from a lethal ch

113 d increased resistance to both foscarnet and cidofovir, compared with the wild-type CMV.

114 comprised of Dryvax and an antiviral agent, cidofovir, could reduce vaccinia viral loads after vacci

115 med Vgamma2Vdelta2 T cells in vaccinia virus/cidofovir-covaccinated macaques mounted major recall-lik

116 te significant lymphopenia (Brincidofovir vs cidofovir; CR = 13 (80%) vs 8 (35%); median lymphocyte c

117 Topical treatment with 1%-cidofovir cream (twice daily for 7 days) was much more e

118 Cidofovir delayed but did not prevent the death of inl i

119 .1% NCT/1.0% NH4Cl, 0.1% NCT/0.1% NH4Cl, and cidofovir demonstrated significantly fewer positive cult

120 Rabbit study 1: 2.5%, 2.0%, 1.0% NCT, and cidofovir demonstrated significantly fewer positive cult

121 nt treatment of ketorolac or diclofenac with cidofovir did not diminish its antiviral inhibitory acti

122 f cellular metabolites showed that levels of cidofovir diphosphate (CDV-DP), the active antiviral com

123 further to the active antiviral metabolite, cidofovir diphosphate.

124 -treated eyes received the authors' standard cidofovir dose regimen: twice daily for 7 days.

125 The 0.5% cidofovir exhibited the most ocular toxicity compared wi

126 susceptibility among 29 paired pre- and post-cidofovir exposure isolates from 22 patients enrolled in

127 nd having viremia <10 000 copies/mL, but not cidofovir exposure.

128 cells and viremia <10 000 copies/mL, but not cidofovir exposure.

129 ddC was more potent than cidofovir for seven of nine serotypes.

130 The efficacy of cidofovir for treatment of cowpox virus infection in BAL

131 T; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up.

132 ir therapy showed complete susceptibility to cidofovir, ganciclovir, and foscarnet.

133 The safety and efficacy of cidofovir gel for treatment of acyclovir-unresponsive he

134 th 20 micrograms of intravitreously injected cidofovir, given at 5- to 6-week intervals, is safe and

135 Five patients in the cidofovir group and seven in the imiquimod group either

136 ts in the electrocautery group, 85.7% in the cidofovir group, and 33% in the sinecatechins group (P <

137 ry group, 82.1% (95% CI: 67.9%-96.3%) in the cidofovir group, and 61.1% (95% CI: 45.2%-77%) in the si

138 n the electrocautery group, 7 (30.4%) in the cidofovir group, and 8 (36.4%) in the sinecatechins grou

139 AD5 variants in tissue culture resistant to cidofovir has important clinical implications with respe

140 virals discussed, including valacyclovir and cidofovir, have not yet been studied in children, but th

141 nging, and salvage therapies, foscarnet, and cidofovir, have significant toxicities.

142 s of HDP-P-GCV and hexadecyloxypropyl-cyclic cidofovir (HDP-cCDV).

143 Cidofovir (HPMPC) is a potent long-acting anticytomegalo

144 d into two topical treatment groups: I, 0.5% cidofovir; II, control vehicle.

145 with wild-type virus with the antiviral drug cidofovir, implicating virus replication and not an inde

146 The antiviral drug cidofovir improved survival in MCMV+ mice, inhibiting MC

147 led resistance to ganciclovir, foscarnet, or cidofovir in 56% of patients receiving maribavir and 68%

148 e was no change in the kinetic parameters of cidofovir in Mrp4 knockout mice.

149 evaluate the safety and antiviral effects of cidofovir in patients with AIDS and asymptomatic sheddin

150 tion in immunosuppression and treatment with cidofovir in the majority.

151 ere resistant to topical treatment with 0.5% cidofovir in the rabbit ocular model.

152 efficacy of the drug 1-O-hexadecyloxypropyl-cidofovir in the RPV/rabbit model and found that an oral

153 with those showing reduced susceptibility to cidofovir in vitro.

154 These data indicate that cidofovir induces rapid cell death through apoptosis in

155 th normal saline were administered with each cidofovir infusion.

156 show that sT sensitizes MCPyV replication to cidofovir inhibition.

157 Cidofovir is a nucleotide analogue of cytosine that has

158 n vitro at nanomolar concentrations, whereas cidofovir is only effective at micromolar concentrations

159 Cidofovir is preemptively used for controlling adenovire

160 Cidofovir is widely used to treat BKVAN, but the magnitu

161 CMX001, an orally active lipid conjugate of cidofovir, is 50 times more active in vitro against herp

162 ovir, intravenous foscarnet, and intravenous cidofovir, is effective.

163 8 tLM, V, a,, = 46.0 pmol/106 cells min) and cidofovir (K, = 58.0 /iM, Vt,ax = 103 pmol/106 cells * m

164 een explored including the adjunctive use of cidofovir, leflunomide, fluoroquinolones, and intravenou

165 egalovirus than HSV-1, liposome-encapsulated cidofovir may prove to be effective local therapy for AI

166 (e.g. Maraviroc, Abacavir, Telbivudine, and Cidofovir) may inhibit Ebola RNA-directed RNA polymerase

167 alone (n=17) or leflunomide plus a course of cidofovir (n=9) and followed them for six to forty month

168 Forty-one episodes (18 = brincidofovir; 23 = cidofovir) of antiviral therapy were observed in 27 pati

169 drugs (NSAIDs) on the antiviral activity of cidofovir on adenovirus replication and the formation of

170 One inoculation of 100 mg/kg cidofovir on day 0, 2, or 4, with respect to aerosol inf

171 hydroxy-2-phosphonylmethoxypropyl) cytosine (cidofovir) on the EBV-associated tumor nasopharyngeal ca

172 received tecovirimat and seven (2%) received cidofovir or brincidofovir.

173 CT/1.0% NH4Cl, 0.1% NCT/0.1% NH4Cl, and 0.5% cidofovir or saline.

174 =8 microM and <30 microM and sensitivity to cidofovir, or high-level ganciclovir-resistant, which ha

175 treated with 2.5%, 2.0%, and 1.0% NCT; 0.5% cidofovir; or saline.

176 developed agents valacyclovir, famciclovir, cidofovir, oral and intraocular ganciclovir, adefovir, r

177 only 2 (9%) major virological responses with cidofovir (P < .0001).

178 ies do not support the usage of leflunomide, cidofovir, quinolones, or IVIGs.

179 om 0.18 to 1.85 microg/mL, whereas those for cidofovir ranged from 0.018 to 5.47 microg/mL.

180 Compared to the control, treatment with 0.5% cidofovir reduced the following: mean Ad titer (days 1 t

181 reatment of the mice with the antiviral drug cidofovir reduced the numbers of effector and memory cel

182 Despite treatment with cidofovir, reduced immunosuppression and maintenance the

183 polyomavirus DNA PCR, but resulted in severe cidofovir-related adverse events.

184 ation early in infection using the antiviral cidofovir rescued CD8(+) T cell cytokine production and

185 al specimen, conferred ganciclovir (GCV) and cidofovir resistance but not foscarnet resistance when i

186 Mutations conferring ganciclovir and cidofovir resistance were detected in CMV from the aqueo

187 reference (IC50 = 6.2 micrograms/ml), stable cidofovir-resistant variants showed fivefold to eightfol

188 of pp71 or treatment with the antiviral drug cidofovir resulted in decreased expression and secretion

189 Cidofovir (S-HPMPC) is a potent broad-spectrum antiviral

190 ptide (12, 13) tyrosine P-O esters of cyclic cidofovir ((S)-cHPMPC, 4) and its cyclic adenine analogu

191 FST-100 and 0.5% cidofovir significantly (P<0.05) reduced viral titers co

192 In vivo, 3% ddC, 2% ddC, and 0.5% cidofovir significantly reduced the number of Ad5-positi

193 patients to topical treatment with either 1% cidofovir (supplied as a gel in a 10 g tube, to last 6 w

194 Thus, no significant changes in cidofovir susceptibilities have been noted for HCMV duri

195 red a borderline decrease in ganciclovir and cidofovir susceptibility, while Q578L and G841S conferre

196 When compared with the alkoxyalkyl esters of cidofovir, the corresponding alkoxyalkyl esters of (S)-H

197 Excluding patients with previous cidofovir therapy did not significantly alter the time c

198 In addition, cidofovir therapy may be useful in the treatment of some

199 Cidofovir therapy provided significant benefits in lesio

200 tained after 14.3 weeks (mean) of first-line cidofovir therapy showed complete susceptibility to cido

201 tinitis progression in patients that were on cidofovir therapy when sensitive isolates were compared

202 ithin 4 to 12 weeks (after 1-4 doses) of the cidofovir therapy, and all patients remain with stable r

203 h CMV retinitis and is unrelated to previous cidofovir therapy.

204 ained after 17.3 weeks (mean) of second-line cidofovir therapy.

205 For Cidofovir, these indices were, respectively, 63.9+/-17.2

206 multaneously treated with the antiviral drug cidofovir to prevent reactivation.

207 :1 (five rabbits per group) to FST-100, 0.5% cidofovir, tobramycin/dexamethasone (Tobradex; Alcon Lab

208 he kinetics of para-aminohippurate (PAH) and cidofovir transport was examined along with its effect o

209 these residues on p-aminohippurate (PAH) and cidofovir transport were assessed by point mutations in

210 ular alphaKG competitively inhibited PAH and cidofovir transport with Ki values ( approximately 5 muM

211 Viral shedding ceased in 13 (87%) of 15 cidofovir-treated and 0 of 9 placebo-treated patients (P

212 pplication site reactions occurred in 25% of cidofovir-treated and 20% of placebo-treated patients; n

213 Ten of 20 cidofovir-treated and none of 10 placebo-treated patient

214 treated animals and were similar to those in cidofovir-treated animals.

215 Cidofovir-treated eyes received the authors' standard ci

216 ere treated four times daily for 7 days, and cidofovir-treated eyes were treated twice daily for 7 da

217 ferences in adenovirus replication among the cidofovir-treated groups (I, II, and III), nor were ther

218 Compared with the control group, all cidofovir-treated groups demonstrated significant antivi

219 ng or >50% decreased area (P = .008); 30% of cidofovir-treated patients versus 0 placebo recipients h

220 For cidofovir-treated patients, median time to complete or g

221 Cidofovir-treated recipients displayed a higher viral lo

222 Median lesion area decreases were 58% for cidofovir-treated versus 0 for placebo-treated patients

223 ber of satellite lesions than was parenteral cidofovir treatment (100 mg/kg/day, given every 3 days).

224 , while lower satisfaction was reported with cidofovir treatment (mean, 4.77 +/- 0.96) (P < .001).

225 duction alone, based on best available data, cidofovir treatment and immunosuppression reduction for

226 d 45 years and above with BKVAN who received cidofovir treatment compared with those who received sta

227 included immunosuppression minimization plus cidofovir treatment for BK nephropathy.

228 significantly more efficacious than the 0.5% cidofovir treatment in the parameters listed above.

229 Cidofovir treatment was discontinued in 10 of 41 patient

230 Topical cidofovir treatment was superior to parenteral treatment

231 Combining topical and parenteral cidofovir treatments provided the greatest reduction in

232 Within the treatment groups, the 1% and 0.5% cidofovir treatments were significantly more effective t

233 Topical 0.5% cidofovir twice daily for 7 days demonstrated significan

234 as to determine the efficacy of topical 0.5% cidofovir twice daily for 7 days on the replication of m

235 ups (16 rabbits/group) were evaluated: I, 1% cidofovir, twice daily for 7 days; II, 0.5% cidofovir, t

236 cidofovir, twice daily for 7 days; II, 0.5% cidofovir, twice daily for 7 days; III, 3% acyclovir oin

237 ginally identified as NKT (e.g. adefovir and cidofovir), two (ddC and ddI) manifested significantly h

238 idofovir mediated major responses in 9 of 11 cidofovir-unresponsive patients and resulted in complete

239 -linked immune absorbent spot at Month 3 and cidofovir use.

240 mune absorbent spot (ELISPOT) at month 3 and cidofovir use.

241 ly (adefovir, used to treat hepatitis B, and cidofovir, used to treat cytomegalovirus infections) wer

242 of ocular toxicity associated with systemic cidofovir (Vistide), sildenafil (Viagra), vigabatrin (Sa

243 he virus until these levels were attained or cidofovir was added.

244 rence to monitoring of renal function before cidofovir was administered and concomitant administratio

245 An intravitreal injection of cidofovir was administered as a therapeutic procedure.

246 In 15 of 32 affected eyes, intravitreous cidofovir was administered as the initial treatment for

247 In mice, cidofovir was also eliminated via the urine by tubular s

248 ombined treatment with a STAT3 inhibitor and cidofovir was effective in improving clinical disease an

249 Cidofovir was efficacious in delaying progression of pre

250 ent uptake of adefovir and tenofovir but not cidofovir was observed only in the membrane vesicles exp

251 passages (1 to 13) at each concentration of cidofovir was performed to obtain robust infectious viru

252 Cidofovir was significantly more effective than NCT in s

253 ant increase in IC50 value was observed when cidofovir was the substrate, but not PAH (a substrate-de

254 y-2-phosphonylmethoxypropyl)cytosine (HPMPC; cidofovir) was evaluated as prophylaxis in a rabbit mode

255 ase-case, the incremental health benefits of cidofovir were 0.0061 life-years saved (2.2 days), with

256 ncentrations for ganciclovir, foscarnet, and cidofovir were 8.6-, 3.4- and 2.9-fold higher than for w

257 Differences in handling of PAH and cidofovir were also observed for the Y230F mutant.

258 Consequently, adefovir and cidofovir were approximately 500-fold and 400-fold more

259 FST-100 and 0.5% cidofovir were both equally effective in reducing viral

260 ous degrees of resistance to ganciclovir and cidofovir were conferred by mutations D301N, N410K, D413

261 nhibitory concentrations (IC(50)) of ddC and cidofovir were determined using standard plaque-reductio

262 Intravitreal levels of cidofovir were low (0.7 microgram/mL) but detectable 120

263 elapsing retinitis) therapy with intravenous cidofovir were obtained from three clinical trials for i

264 Little uptake was determined for cidofovir, whereas PAH uptake was similar to wild-type h

265 The cyclic prodrug of cidofovir, which exhibits reduced in vivo nephrotoxicity